Once safety is completed which we get ethics approval in Jan and first results in Feb plus we get confirmation through Walter Reed from any positive TBI potential in the middle of Jan which gives us future non dilutive funding of grants up to 40 million dollars.
The mechanism of inhibiting calcium influx to protect the brain is well established over the past 3 decades but what they have failed to accomplish is having a drug that avoids glutamate completely avoiding side effects and glutamate in humans actually promotes neuronal survival in TBI and stroke which is the opposite in animals. NYR the first drug in its drug class on safety clearance will be only a matter of time before it becomes a billion dollars plus company on phase 2 with a 60 billion dollar unmet market potential and which not only targets primary and secondary brain injury on stroke but protects the heart from damage and allowing the patients to avoid future heart failure which can happen within 30 days of discharge
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)